From PR:
We will conduct a thorough analysis of all the data, and expect to present detailed Phase 3 lung cancer trial results later this year. Meanwhile, we are scheduled to present new NOV-002 preclinical data at the AACR Annual Meeting in April 2010, and we are on track for results from a NOV-002 Phase 2 breast cancer trial in 3Q 2010. We are also on track to initiate a Phase 2 hepatitis C trial shortly, with our second compound NOV-205."
From reading this, there is alot in the pipeline. I assume "shortly" means very soon. Also, there should be news again about the April Meeting. I'm sure the company is ready to get this going in the right direction.
Market Data 
Markets 
AI
